NCT07357532尚未招募2 期
Exploration of Treatment Strategies After Concurrent Chemoradiotherapy for Limited-stage Small Cell Lung Cancer (LS-SCLC) Guided by Molecular Residual Disease (MRD)
Peking University Cancer Hospital & Institute0 个研究点目标入组 44 人开始时间: 2026年1月31日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 44
研究概览
简要总结
This study plans to enroll limited-stage small cell lung cancer (LS-SCLC) patients who have achieved disease control after concurrent chemoradiotherapy (cCRT). Tissue samples collected at initial diagnosis and serial peripheral blood samples obtained at multiple post-cCRT timepoints will be analyzed using targeted next-generation sequencing to investigate the correlation between molecular residual disease (MRD) status and tumor recurrence/metastasis. For patients with MRD-positive results, a therapeutic strategy combining immunotherapy with anti-angiogenic agents will be implemented with the aim of improving clinical outcomes.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed informed consent; age >18 and <80 years;
- •Histologically or cytologically confirmed limited-stage small cell lung cancer (LS-SCLC);
- •Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0-1;
- •Patients who have achieved disease stabilization after concurrent or sequential chemoradiotherapy;
- •Patients who had not received previous immune checkpoint inhibitor treatment;
- •Patients with MRD-positive status following concurrent chemoradiotherapy;
- •Willingness to provide clinical-pathological data, imaging studies, and other required materials for research purposes; compliance with follow-up procedures, including blood sample collection at predefined efficacy evaluation timepoints; and agreement to use the collected data for subsequent research analyses.
排除标准
- •Have other malignant tumors;
- •Autoimmune disorders that are not amenable to PD-L1 inhibitor therapy;
- •Prior exposure to other anti-angiogenic small molecule TKIs such as erlotinib or anti-angiogenic monoclonal antibodies such as bevacizumab (except locally infused bevacizumab); or participation in a clinical trial of another antineoplastic agent within 4 weeks prior to the first dose of ; or prior treatment with a paclitaxel;
- •Uncontrolled hypertension (systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg despite optimal pharmacologic therapy);
- •Class II or greater myocardial ischemia or myocardial infarction, poorly controlled arrhythmias (including QTc intervals ≥450 ms in men and ≥470 ms in women). According to NYHA criteria, grade III-IV cardiac insufficiency, or cardiac color ultrasound suggests that the left ventricular ejection fraction (LVEF) is <50% have had a myocardial infarction within 6 months prior to enrollment, New York Heart Association class II or higher heart failure, uncontrolled angina pectoris, uncontrolled severe ventricular arrhythmia, clinically significant pericardial disease, or ECG suggestive of acute ischemia or active conduction system abnormalities; (6) uncontrolled angina pectoris, uncontrolled severe ventricular arrhythmias, clinically significant pericardial disease, or ECG suggestive of acute ischemia or active conduction system abnormalities.
- •Uncontrolled co-morbidities including, but not limited to, poorly controlled diabetes mellitus, diabetic peripheral lesions , persistent infections, or psychiatric or social conditions that may interfere with the subject's ability to comply;
- •Abnormal coagulation (INR > 1.5 or Prothrombin Time (PT) > ULN + 4 seconds or APTT > 1.5 ULN), hemorrhagic symptoms, or on thrombolytic or anticoagulant therapy;
- •Known hereditary or acquired bleeding and thrombotic disorders such as hemophilia, coagulation disorders, thrombocytopenia, hypersplenism, etc.;
- •Significant coughing up of fresh blood or hemoptysis of one-half teaspoon (2.5 ml) per day or more within 2 months prior to entry into the study ;
- •Failure to receive specified treatment or change in treatment regimen prior to disease progression;
- •Unable to cooperate with the study in accordance with the established clinical follow-up period;
- •Unable to accept or provide the specified means of efficacy assessment such as imaging.
- •Pregnant or lactating women.
研究者
相似试验
撤回
1 期
Bispecific T-Cell Engager Tarlatamab and TROP2 Targeted Antibody Drug Conjugate Sacituzumab Govitecan in Previously Treated Extensive-Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine CancerSmall Cell CarcinomaExtensive-Stage Small Cell Lung CancerNCT07328490National Cancer Institute (NCI)120
进行中（未招募）
不适用
Evaluation of Efficacy of Minimally Invasive Local Therapy for Lung Tumors and Its Impact on Breathing FunctionNCT07272356Aurimas Macionis68
招募中
2 期
QL1706 Combined With Chemotherapy in the Treatment of Immune-mediated NSCLCNCT07330596Anhui Provincial Cancer Hospital96
进行中（未招募）
1/2 期
[177Lu]Lu-DOTA-TATE 联合卡铂、依托泊苷和阿替利珠单抗治疗新诊断的 ES-SCLC 参与者的安全性和疗效研究CTR2025206310
招募中
不适用
Patient-derived Tumor-like Cell Cluster Model-based Precision Treatment Strategy on Non-small Cell Lung CancerNon-small Cell Lung CancerNCT07328945Shanghai Pulmonary Hospital, Shanghai, China250